Vivus gets anti-obesity patent

By Elaine Rigoli

Tampa, Fla., June 13 - Vivus, Inc. announced Tuesday that the U.S. Patent and Trademark Office has issued the company's first patent for Qnexa, an investigational oral treatment for obesity.

This patent, number U.S. 7,056,890 B2, broadly covers the Qnexa product and its use in the treatment of obesity, according to a news release.

The company said Qnexa, which now has patent protection until 2019, is the subject of multiple additional U.S. and foreign patent applications.

Vivus recently announced positive results from a phase 2 study of Qnexa, which among other findings, showed that more than 50% of patients experienced 10% or more total body weight loss in 24 weeks.

Qnexa is believed to work by suppressing appetite and lowering the threshold for satiety, the two main mechanisms that impact eating behavior.

In 2004, the U.S. Centers for Disease Control and Prevention ranked obesity as the number one health threat in America.

Located in Mountain View, Calif., Vivus is a pharmaceutical company dedicated to the development and commercialization of products addressing obesity and sexual health.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.